고양이 백신 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of feline vaccines Market

The global feline vaccines market was valued at USD 1.67 billion in 2025 and is projected to grow to USD 1.76 billion in 2026, reaching USD 3.21 billion by 2034, reflecting a CAGR of 7.83% during the forecast period. North America dominated the market in 2025 with a 42.77% share, driven by rising cat ownership, advanced veterinary healthcare infrastructure, and awareness among pet owners regarding preventive care. Feline vaccines protect cats from serious illnesses such as feline panleukopenia, feline respiratory diseases, calicivirus, herpesvirus, rabies, and feline leukemia virus (FeLV). The increasing prevalence of these diseases globally, coupled with the growth of veterinary services and research initiatives, is propelling the market's expansion.

Key players such as Zoetis Services LLC, Merck & Co., Inc., and Elanco have been focusing on innovative vaccines offering broader protection and longer-lasting immunity, thus further accelerating market growth. For example, a study conducted in Campania, Italy (2019-2021) revealed that 73.5% of 328 domestic cats tested positive for feline panleukopenia virus, indicating high demand for active vaccination programs.

Market Dynamics

Drivers: The growth of the feline vaccines market is largely driven by rising cat ownership and the increasing demand for preventive healthcare. In 2023-2024, the American Pet Products Association reported 49 million U.S. households owning a cat, representing 37% of pet-owning households. Additionally, the rising prevalence of feline diseases like rabies and FeLV encourages owners to vaccinate their pets, fueling market expansion.

Restraints: Limited access to veterinary services in developing regions poses a significant restraint. For example, in Kenya, only 410 veterinarians were available in 2022, limiting vaccine adoption.

Opportunities: Government initiatives for feline vaccination present growth opportunities. In July 2025, Nashik Municipal Corporation (India) launched a program to sterilize and vaccinate stray cats against rabies, reflecting increasing institutional support to prevent zoonotic disease spread.

Challenges: Vaccine hesitancy among pet owners, due to concerns over safety, side effects, and awareness gaps, continues to challenge market growth. The AVMA reported in January 2024 that some cat owners remain reluctant to vaccinate their pets, impacting adoption rates.

Market Trends

Innovations in vaccine platforms for feline diseases are a key trend. For instance, in September 2024, Merck & Co., Inc. expanded its NOBIVAC NXT platform to include FeLV, offering advanced protection against feline leukemia virus. Such developments demonstrate a focus on high-efficacy, long-lasting, and safer vaccines for cats.

Segmentation Analysis

By Technology:

• Inactivated vaccines dominate due to high safety profiles and government-supported programs, particularly against rabies. In March 2024, Merck donated NOBIVAC rabies vaccines under the Mission Rabies initiative.
• Live attenuated vaccines are increasingly used for diseases like feline panleukopenia.
• Recombinant vaccines and others are projected to grow rapidly due to technological advancements and rising prevalence of feline diseases.

By Disease Type:

• Rabies held the largest share in 2024, driven by zoonotic risks. AVMA reported 222 rabies cases in cats in 2023.
• Feline leukemia virus (FeLV) is expected to grow significantly; a survey in Chile reported FeLV prevalence of 54.9% among 182 domestic cats.
• Feline viral rhinotracheitis and other diseases are growing at a moderate pace.

By Route of Administration:

• Parenteral vaccines dominate due to higher efficacy and rapid onset.
• Intranasal vaccines are expanding due to stress-free administration and quick immune response. For example, Elanco's Feline UltraNasal FVRCP vaccine protects against three major diseases in cats.

By Distribution Channel:

• Veterinary hospitals dominate, driven by awareness campaigns and partnerships such as Virbac with WSAVA in October 2022.
• Veterinary clinics are expanding with initiatives like Petco Love's free vaccination drive in March 2025.
• Pharmacies and other channels are expected to grow steadily, offering convenient access to vaccines.

Regional Outlook

• North America: Market valued at USD 0.71 billion in 2025, driven by high cat ownership and advanced veterinary services. The U.S. accounts for the largest regional share.
• Europe: Strong growth expected, with 10.8 million pet cats in the U.K. (PDSA 2024).
• Asia Pacific: Fastest CAGR anticipated due to rising awareness and increasing number of pet cats; Australia reported 4.9 million pet cats in 2024.
• Latin America & Middle East & Africa: Moderate growth driven by government-led vaccination programs, such as Animal Welfare Abu Dhabi initiative in February 2025.

Competitive Landscape

The market is semi-consolidated with key players like Zoetis Services LLC, Merck & Co., Inc., Elanco, Virbac, Ceva, and Boehringer Ingelheim. These companies leverage product innovation, strategic partnerships, and global presence to strengthen market position. Recent developments include:

• August 2025: Bioveta launched Biofel vaccines for cats and Biocan for dogs in Venezuela.
• September 2024: Merck launched NOBIVAC NXT FeLV.
• June 2024: Merck expanded NOBIVAC NXT Rabies portfolio in Canada.

Conclusion

The global feline vaccines market is projected to grow from USD 1.67 billion in 2025 to USD 1.76 billion in 2026, reaching USD 3.21 billion by 2034 at a CAGR of 7.83%. Growth is driven by rising cat ownership, awareness of preventive care, government initiatives, and advances in vaccine technology. North America dominates, while Asia Pacific exhibits the fastest growth. Despite challenges like limited access in developing countries and vaccine hesitancy, innovations in vaccine platforms, intranasal vaccines, and strategic expansions of major players are expected to sustain market growth throughout the forecast period.

Segmentation By Technology

• Inactivated
• Live Attenuated
• Recombinant
• Others

By Disease Type

• Feline Viral Rhinotracheitis
• Rabies
• Feline Leukemia Virus
• Others

By Route of Administration

• Parenteral
• Intranasal

By Distribution Channel

• Veterinary Hospitals
• Veterinary Clinics
• Pharmacies & Drug Stores
• Others

By Region

• North America (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
  • U.S.
  • Canada
• Europe (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Technology, By Disease Type, By Route of Administration, By Distribution Channel, By Country/ Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview of Feline Diseases by Key Countries, By Key Countries/ Region, 2025
• 4.2. Regulatory Scenario by Key Countries/ Region, 2025
• 4.3. Overview of Vaccination for Feline Diseases
• 4.4. New Technology Launches, By Key Players
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Feline Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Technology
  • 5.1.1. Inactivated
  • 5.1.2. Live Attenuated
  • 5.1.3. Recombinant
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Disease Type
  • 5.2.1. Feline Viral Rhinotracheitis
  • 5.2.2. Rabies
  • 5.2.3. Feline Leukemia Virus
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Parenteral
  • 5.3.2. Intranasal
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Veterinary Hospitals
  • 5.4.2. Veterinary Clinics
  • 5.4.3. Pharmacies & Drug Stores
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Feline Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Technology
  • 6.1.1. Inactivated
  • 6.1.2. Live Attenuated
  • 6.1.3. Recombinant
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Disease Type
  • 6.2.1. Feline Viral Rhinotracheitis
  • 6.2.2. Rabies
  • 6.2.3. Feline Leukemia Virus
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Parenteral
  • 6.3.2. Intranasal
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Veterinary Hospitals
  • 6.4.2. Veterinary Clinics
  • 6.4.3. Pharmacies & Drug Stores
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Feline Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Technology
  • 7.1.1. Inactivated
  • 7.1.2. Live Attenuated
  • 7.1.3. Recombinant
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Disease Type
  • 7.2.1. Feline Viral Rhinotracheitis
  • 7.2.2. Rabies
  • 7.2.3. Feline Leukemia Virus
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Parenteral
  • 7.3.2. Intranasal
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Veterinary Hospitals
  • 7.4.2. Veterinary Clinics
  • 7.4.3. Pharmacies & Drug Stores
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Feline Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Technology
  • 8.1.1. Inactivated
  • 8.1.2. Live Attenuated
  • 8.1.3. Recombinant
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Disease Type
  • 8.2.1. Feline Viral Rhinotracheitis
  • 8.2.2. Rabies
  • 8.2.3. Feline Leukemia Virus
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Parenteral
  • 8.3.2. Intranasal
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Veterinary Hospitals
  • 8.4.2. Veterinary Clinics
  • 8.4.3. Pharmacies & Drug Stores
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Feline Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Technology
  • 9.1.1. Inactivated
  • 9.1.2. Live Attenuated
  • 9.1.3. Recombinant
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Disease Type
  • 9.2.1. Feline Viral Rhinotracheitis
  • 9.2.2. Rabies
  • 9.2.3. Feline Leukemia Virus
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Parenteral
  • 9.3.2. Intranasal
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Veterinary Hospitals
  • 9.4.2. Veterinary Clinics
  • 9.4.3. Pharmacies & Drug Stores
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Feline Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Technology
  • 10.1.1. Inactivated
  • 10.1.2. Live Attenuated
  • 10.1.3. Recombinant
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Disease Type
  • 10.2.1. Feline Viral Rhinotracheitis
  • 10.2.2. Rabies
  • 10.2.3. Feline Leukemia Virus
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Parenteral
  • 10.3.2. Intranasal
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Veterinary Hospitals
  • 10.4.2. Veterinary Clinics
  • 10.4.3. Pharmacies & Drug Stores
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Technology, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.2.1. Elanco
  • 11.2.2. Boehringer Ingelheim International GmbH
  • 11.2.3. Virbac
  • 11.2.4. Merck & Co., Inc.
  • 11.2.5. Zoetis Services LLC
  • 11.2.6. Ceva
  • 11.2.7. Bioveta, a.s.